Andrew Satz, CEO of EVQLV, explains how our technology works, with specific attention to our progress on COVID-19.
EVQLV’s very own Andrew Satz (CEO and CO-Founder) was a guest on the M2 Techcast of MITechNews.com with Mike Brennan and Matt Roush. He discussed our work on coronavirus, what is and isn’t artificial intelligence, the application of AI, and our mission at EVQLV.
BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.
EVQLV is excited to announce we’ve joined the BAJ Accelerator. The accelerator runs from Monday, May 18th to Friday, May 22nd. We’re confident BAJ will provide the necessary support and resources we need to reach the next level in our journey.
EVQLV uses artificial intelligence (AI) to discover and optimize novel biologics. Our algorithm uses an evolutionary approach with applied external pressures to generate candidates. There’s a lot more to it, but we thought you might enjoy a taste of our “secret sauce.”
We’re not sharing this information to scare, but instead to inform on the challenges the healthcare industry is facing. With that in mind, below we report on 21 innovative efforts from leading and emerging players in the biotech industry to combat the COVID-19 pandemic.
Our co-founder and CEO, Andrew Satz, recently gave a talk to data science students at the Flatiron School. One of the questions he covered was the difference between In Silico, In Vivo and In Vitro.
BioIDEA and EVQLV are hosting a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.
Our CEO, Andrew Satz, has spent the last 15 years working remotely — making him a veritable expert on the skill. He was recently a guest on the Gaper podcast where he shared three methods you can quickly implement to help you adjust to remote work.
EVQLV is excited to announce we took first place in Columbia Engineering’s Venture Competition (CVC). We would like to give a special thanks to all fellow companies, the wonderful judges, and of course, Columbia Engineering.
The World Health Organization (WHO), yesterday, released a public statement for collaboration on COVID-19 treatment development of which Andrew Satz (CEO, EVQLV) gladly joined his name.
Our very own Brett Averso (CTO, EVQLV) was welcomed on the AI Podcast in 26.1 Minutes with hosts Brian Ray and Don Sheu. They discussed our work on COVID-19 with ImmunoPrecise, the benefits of a computational approach to antibody research and drug discovery, our progress as a company and a host of other topics.